NCT04920981 (CLINATEZO) is a clinical trial of atezolizumab in Small Cell Lung Cancer, sponsored by Intergroupe Francophone de Cancerologie Thoracique.

Who is sponsoring NCT04920981?

NCT04920981 is sponsored by Intergroupe Francophone de Cancerologie Thoracique.

What drugs are being tested in NCT04920981?

Interventions in NCT04920981: atezolizumab.

What condition does NCT04920981 study?

NCT04920981 studies Small Cell Lung Cancer.

Is NCT04920981 still recruiting?

NCT04920981 is currently completed. Last updated 7 November 2024.

Last reviewed 2024-11-07 · How we verify

NCT04920981: CLINATEZO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Atezolizumab Combined With Chemotherapy in Extensive Stage SCLC

Completed Last updated 7 November 2024

What this trial tests

trial testing atezolizumab in Small Cell Lung Cancer in 518 participants. Completed in 1 September 2024.

Timeline

2 February 2021

Primary endpoint
24 November 2021

1 September 2024

Quick facts

Lead sponsor	Intergroupe Francophone de Cancerologie Thoracique
Status	Completed
Study type	OBSERVATIONAL
Enrollment	518
Start date	2 February 2021
Primary completion	24 November 2021
Estimated completion	1 September 2024
Sites	2 locations across France

Drugs / interventions tested

atezolizumab (atezolizumab) — full drug profile →

Conditions studied

Small Cell Lung Cancer — all drugs for Small Cell Lung Cancer →

Sponsor

Intergroupe Francophone de Cancerologie Thoracique — full company profile →

Who can join

18 and older, any sex, with Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

CLINATEZO cohort will evaluate overall survival, real world progression-free survival, best response and duration of treatment in patients with advanced, metastatic Small Cell Lung Cancer (SCLC) who received atezolizumab combined with chemotherapy part of the French Early Access Program (ATU). Subsequent treatments (treatment delivered immediately after treatment with atezolizumab and chemotherapy) will be recorded. Those outcomes will be correlated to clinical, pathological, and radiological characteristics of patients.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Long-Term Response and Survival in Extensive-Stage SCLC Receiving Atezolizumab Plus Chemotherapy in a Real-World Setting: IFCT-1905 CLINATEZO
Falchero L, Amrane K, Godbert B, Leterre B, et al · · 2026

Verify or expand the search:

Other trials of atezolizumab

Trials testing the same drug.

NCT07472517 — DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carbop · Phase 3 · not yet recruiting
NCT05733611 — RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC · Phase 2 · terminated
NCT05834348 — A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in N · completed
NCT04471415 — Study to Investigate DRP-104 in Adults With Advanced Solid Tumors · Phase 1, PHASE2 · terminated
NCT04123470 — A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant Melanoma · Phase 1, PHASE2 · completed

Other recruiting trials for Small Cell Lung Cancer

Currently open trials in the same condition.

NCT07476287 — Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult · Phase 2 · recruiting
NCT07296809 — SKB500 Combinations in Patients With Small Cell Lung Cancer · Phase 2 · recruiting
NCT07155200 — Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial) · Phase 1, PHASE2 · recruiting
NCT06922539 — ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer · Phase 1 · recruiting
NCT07373964 — A Prospective, Single-Arm, Single-Center Phase II Study Evaluating the Efficacy and Safety of Chidamide Combined With PD · Phase 2 · recruiting

Other Intergroupe Francophone de Cancerologie Thoracique trials

Trials by the same sponsor.

NCT07420439 — Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease · Phase 2 · not yet recruiting
NCT06937905 — Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic P · Phase 3 · recruiting
NCT06908993 — Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Trea · Phase 3 · recruiting
NCT06840834 — Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previo · Phase 2 · recruiting
NCT05285033 — RW Effectiveness of Lurbinectedin in Extensive Stage SCLC · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04920981 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Intergroupe Francophone de Cancerologie Thoracique
Last refreshed: 7 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04920981.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing